Derrick Wong, MD
Hematology/Oncology · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 2 carriers
- Offices
- 7
Offices
7 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
14 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wong’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A82274 · Current
Licensed to practise in California · since 2003 · expires 2027-01-31 · University of California, Los Angeles School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$3,147,609
Medicare paid this office $3,147,609 for 905 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 19 | $724,905 | None |
| Injection, pembrolizumab, 1 mg | 24 | $449,319 | None |
| Injection, vedolizumab, intravenous, 1 mg | 15 | $171,721 | None |
| Long return visit (40+ min) | 273 | $126,541 | $164 |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 13 | $90,226 | None |
See all 47 services
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 19 | $724,905 | None |
| Injection, pembrolizumab, 1 mg | 24 | $449,319 | None |
| Injection, vedolizumab, intravenous, 1 mg | 15 | $171,721 | None |
| Long return visit (40+ min) | 273 | $126,541 | $164 |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 13 | $90,226 | None |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 12 | $81,627 | None |
| Injection, tocilizumab, 1 mg | 12 | $52,615 | None |
| Injection, denosumab, 1 mg | 15 | $46,416 | None |
| Return visit (30+ min) | 287 | $43,225 | $109 |
| Administration of chemotherapy into vein, 1 hour or less | 122 | $42,127 | $139 |
| Injection, infliximab, excludes biosimilar, 10 mg | 15 | $35,783 | None |
| Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 17 | $30,134 | $109 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 18 | $29,571 | $16 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 26 | $20,360 | None |
| New patient visit (60+ min) | 86 | $17,531 | $204 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 125 | $17,152 | $66 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 24 | $11,434 | $78 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 343 | $8,141 | $15 |
| Administration of additional new drug or substance into vein, 1 hour or less | 49 | $7,996 | $68 |
| Instillation of anti-cancer drug into bladder | 21 | $6,535 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $5,757 | $107 |
| Bcg live intravesical instillation, 1 mg | 15 | $5,018 | None |
| Injection of additional new drug or substance into vein | 68 | $4,081 | $16 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 65 | $3,961 | $30 |
| Administration of chemotherapy into vein, each additional hour | 45 | $3,583 | $29 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,113 | $156 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 30 | $2,965 | $21 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 43 | $2,934 | $30 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 34 | $2,540 | $37 |
| Administration of additional new drug or substance into vein using push technique | 22 | $2,220 | $58 |
| Injection of drug or substance under skin or into muscle | 70 | $2,215 | $14 |
| New patient visit (45+ min) | 15 | $2,091 | $139 |
| Injection of drug or substance into vein | 47 | $1,879 | $34 |
| Drawing of blood for a medical problem | 12 | $1,713 | $90 |
| Irrigation of implanted venous access drug delivery device | 24 | $1,460 | $26 |
| Injection, zoledronic acid, 1 mg | 59 | $1,411 | None |
| Injection, fosaprepitant, 1 mg | 36 | $1,104 | None |
| Injection, carboplatin, 50 mg | 29 | $913 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 24 | $688 | $20 |
| Injection, paclitaxel, 1 mg | 21 | $669 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 15 | $367 | $24 |
| Injection, methylprednisolone sodium succinate, 5 mg | 11 | $272 | None |
| Infusion, normal saline solution, 250 cc | 168 | $149 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 49 | $109 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 46 | $94 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 44 | $61 | None |
| Unclassified drugs | 24 | $24 | None |
Who their Medicare patients are
905 Original Medicare patients in 2024. Average age 77 · Under 65 3% · 85 and older 19% · Women 56% · Also on Medicaid 9% · Health risk score 1.55. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 66% · Cancer 42% · Chronic kidney disease 28% · Diabetes 25% · Coronary heart disease 22% · Atrial fibrillation 17% · Depression 16% · Heart failure 13% · COPD 10% · Dementia 6% · Stroke 5%.
The office billed $10,472,988, Medicare allowed $3,980,432 and paid $3,147,609; for 161,982 services of 134 kinds; $2,816,057 of it was for drugs given in the office and $331,553 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 905 | 161,982 | 77 | 1.55 | $10,472,988 | $3,147,609 |
| 2023 | 851 | 193,143 | 77 | 1.64 | $10,517,116 | $3,198,282 |
| 2022 | 836 | 211,841 | 76 | 1.57 | $11,630,533 | $3,914,120 |
| 2021 | 827 | 143,670 | 76 | 1.64 | $8,482,680 | $2,962,516 |
| 2020 | 713 | 129,348 | 76 | 1.79 | $7,060,945 | $2,374,646 |
| 2019 | 831 | 178,520 | 76 | 1.70 | $10,293,781 | $3,275,829 |
| 2018 | 838 | 228,181 | 76 | 1.55 | $13,370,736 | $4,255,002 |
| 2017 | 783 | 133,253 | 76 | 1.71 | $9,321,215 | $2,836,333 |
| 2016 | 808 | 188,305 | 76 | 1.66 | $10,389,244 | $2,966,401 |
| 2015 | 726 | 126,139 | 75 | 1.66 | $5,624,925 | $1,603,555 |
| 2014 | 464 | 86,127 | 74 | 1.66 | $4,540,067 | $1,150,568 |
| 2013 | 600 | 61,295 | 74 | 1.67 | $5,261,949 | $1,311,720 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 47 services
| Injection, pembrolizumab, 1 mg | 27 | $809,653 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 17 | $489,067 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 17 | $171,979 | None |
| Long return visit (40+ min) | 248 | $119,526 | $163 |
| Injection, tocilizumab, 1 mg | 13 | $60,217 | None |
| Administration of chemotherapy into vein, 1 hour or less | 123 | $49,563 | $144 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 11 | $47,010 | None |
| Return visit (30+ min) | 276 | $41,430 | $111 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 13 | $40,261 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 16 | $37,506 | None |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 15 | $36,567 | $23 |
| Injection, denosumab, 1 mg | 11 | $26,280 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 145 | $23,642 | $70 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 28 | $19,400 | None |
| New patient visit (60+ min) | 63 | $12,606 | $200 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $9,954 | $80 |
| Administration of additional new drug or substance into vein, 1 hour or less | 45 | $9,263 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $7,350 | $110 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 19 | $5,478 | $0 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 51 | $5,406 | $31 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 71 | $4,764 | $30 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 47 | $4,422 | $22 |
| Administration of additional new drug or substance into vein using push technique | 21 | $4,291 | $60 |
| Administration of chemotherapy into vein, each additional hour | 38 | $4,234 | $30 |
| Injection of additional new drug or substance into vein | 66 | $3,648 | $17 |
| Instillation of anti-cancer drug into bladder | 15 | $3,602 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,518 | $160 |
| Injection of drug or substance under skin or into muscle | 59 | $3,176 | $14 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 37 | $2,952 | $36 |
| Bcg live intravesical instillation, 1 mg | 11 | $2,496 | None |
| Injection of drug or substance into vein | 39 | $2,467 | $39 |
| Injection, zoledronic acid, 1 mg | 52 | $1,865 | None |
| Drawing of blood for a medical problem | 11 | $1,586 | $93 |
| Irrigation of implanted venous access drug delivery device | 19 | $1,140 | $27 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 25 | $1,086 | $21 |
| Injection, fosaprepitant, 1 mg | 23 | $1,045 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 17 | $938 | None |
| Injection, paclitaxel, 1 mg | 13 | $738 | None |
| Collection of blood sample from implanted device | 11 | $668 | $24 |
| Infusion into a vein for hydration, each additional hour | 32 | $622 | $13 |
| Injection, carboplatin, 50 mg | 15 | $581 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $296 | $25 |
| Injection, dexamethasone sodium phosphate, 1 mg | 54 | $150 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 57 | $145 | None |
| Infusion, normal saline solution, 250 cc | 162 | $140 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 13 | $90 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 33 | $49 | None |
2022: 39 services
| Injection, pembrolizumab, 1 mg | 31 | $1,054,933 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 14 | $540,894 | None |
| Injection, vedolizumab, intravenous, 1 mg | 11 | $151,530 | None |
| Long return visit (40+ min) | 286 | $138,290 | $164 |
| Administration of chemotherapy into vein, 1 hour or less | 130 | $69,251 | $150 |
| Injection, infliximab, excludes biosimilar, 10 mg | 16 | $49,864 | None |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 11 | $48,216 | $35 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 11 | $36,607 | None |
| Injection, denosumab, 1 mg | 12 | $36,058 | None |
| Return visit (30+ min) | 253 | $35,423 | $106 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 126 | $25,830 | $73 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 23 | $15,737 | None |
| New patient visit (60+ min) | 63 | $12,755 | $202 |
| Administration of additional new drug or substance into vein, 1 hour or less | 47 | $10,694 | $73 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 20 | $9,830 | $83 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 65 | $8,536 | $32 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 12 | $7,133 | $1 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 78 | $5,481 | $30 |
| Injection of additional new drug or substance into vein | 74 | $5,072 | $17 |
| Administration of chemotherapy into vein, each additional hour | 51 | $4,261 | $31 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 23 | $3,704 | $22 |
| Injection of drug or substance under skin or into muscle | 64 | $3,534 | $14 |
| Instillation of anti-cancer drug into bladder | 12 | $3,397 | $89 |
| Administration of additional new drug or substance into vein using push technique | 17 | $3,364 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $3,010 | $94 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 32 | $2,770 | $36 |
| Injection, zoledronic acid, 1 mg | 66 | $2,163 | None |
| New patient visit (45+ min) | 12 | $1,869 | $156 |
| Injection of drug or substance into vein | 33 | $1,834 | $42 |
| Collection of blood sample from implanted device | 16 | $1,321 | $29 |
| Injection, fosaprepitant, 1 mg | 28 | $1,309 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 15 | $1,132 | None |
| Injection, carboplatin, 50 mg | 32 | $1,047 | None |
| Injection, paclitaxel, 1 mg | 23 | $1,043 | None |
| Irrigation of implanted venous access drug delivery device | 23 | $989 | $29 |
| Injection, dexamethasone sodium phosphate, 1 mg | 67 | $220 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 69 | $126 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 37 | $100 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 14 | $35 | None |
2021: 40 services
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 13 | $582,695 | None |
| Injection, pembrolizumab, 1 mg | 21 | $536,166 | None |
| Long return visit (40+ min) | 266 | $124,727 | $162 |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 13 | $71,132 | None |
| Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 12 | $54,874 | $191 |
| Administration of chemotherapy into vein, 1 hour or less | 118 | $48,926 | $161 |
| Injection, denosumab, 1 mg | 18 | $48,093 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 15 | $47,315 | None |
| Return visit (30+ min) | 237 | $33,536 | $112 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 112 | $18,299 | $79 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 27 | $15,118 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 25 | $14,502 | $89 |
| New patient visit (60+ min) | 65 | $13,922 | $214 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 15 | $8,572 | $1 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $6,592 | $96 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 59 | $6,530 | $34 |
| Administration of additional new drug or substance into vein, 1 hour or less | 35 | $6,055 | $78 |
| Administration of chemotherapy into vein, each additional hour | 43 | $3,470 | $33 |
| Injection of additional new drug or substance into vein | 63 | $3,321 | $18 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,963 | $185 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 47 | $2,868 | $31 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 26 | $2,674 | $23 |
| Administration of additional new drug or substance into vein using push technique | 16 | $2,604 | $67 |
| Administration of chemotherapy into vein using push technique | 13 | $2,343 | $123 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 37 | $2,237 | $35 |
| New patient visit (45+ min) | 14 | $2,016 | $144 |
| Injection of drug or substance under skin or into muscle | 56 | $1,980 | $14 |
| Injection, zoledronic acid, 1 mg | 35 | $1,877 | None |
| Injection, fosaprepitant, 1 mg | 22 | $1,520 | None |
| Injection of drug or substance into vein | 23 | $1,390 | $45 |
| Irrigation of implanted venous access drug delivery device | 24 | $1,072 | $30 |
| Injection, paclitaxel, 1 mg | 18 | $768 | None |
| Telephone medical discussion provided by nonphysician professional, 21-30 minutes | 19 | $629 | $33 |
| Collection of blood sample from implanted device | 12 | $626 | $28 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $503 | None |
| Injection, carboplatin, 50 mg | 21 | $471 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 60 | $161 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 57 | $99 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 35 | $50 | None |
| Infusion, normal saline solution, 250 cc | 22 | $13 | None |
2020: 41 services
| Injection, pembrolizumab, 1 mg | 21 | $458,909 | None |
| Injection, rituximab, 10 mg | 13 | $81,118 | None |
| Return visit (30+ min) | 366 | $69,697 | $96 |
| Injection, denosumab, 1 mg | 18 | $52,998 | None |
| Administration of chemotherapy into vein, 1 hour or less | 131 | $51,950 | $152 |
| Injection, infliximab, excludes biosimilar, 10 mg | 17 | $45,977 | None |
| Injection, pegfilgrastim, 6 mg | 11 | $42,744 | None |
| Long return visit (40+ min) | 138 | $36,472 | $135 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 18 | $12,711 | None |
| New patient visit (60+ min) | 57 | $11,295 | $198 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 82 | $10,722 | $76 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $8,125 | $86 |
| Administration of additional new drug or substance into vein, 1 hour or less | 44 | $7,715 | $73 |
| Red blood cells, leukocytes reduced, each unit | 15 | $7,052 | $144 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 61 | $5,572 | $33 |
| Injection, fosaprepitant, 1 mg | 21 | $5,342 | None |
| Administration of chemotherapy into vein, each additional hour | 50 | $4,758 | $32 |
| Injection of additional new drug or substance into vein | 80 | $4,438 | $17 |
| Administration of additional new drug or substance into vein using push technique | 19 | $3,152 | $63 |
| Telephone medical discussion with physician, 21-30 minutes | 22 | $2,761 | $102 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 26 | $2,263 | $23 |
| Injection of drug or substance into vein | 28 | $1,888 | $42 |
| New patient visit (45+ min) | 12 | $1,832 | $153 |
| Irrigation of implanted venous access drug delivery device | 34 | $1,645 | $28 |
| Injection of drug or substance under skin or into muscle | 57 | $1,584 | $14 |
| Instillation of anti-cancer drug into bladder | 11 | $1,459 | $86 |
| Transfusion of blood or blood products | 15 | $1,248 | $39 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 13 | $1,247 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 21 | $1,241 | $34 |
| Injection, zoledronic acid, 1 mg | 25 | $1,084 | None |
| Influenza vaccine split virus, preservative free | 16 | $976 | $61 |
| Injection, paclitaxel, 1 mg | 20 | $864 | None |
| Injection, carboplatin, 50 mg | 26 | $778 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 22 | $629 | $22 |
| Infusion into a vein for hydration, each additional hour | 13 | $526 | $14 |
| Administration of influenza virus vaccine | 16 | $335 | $21 |
| Injection, dexamethasone sodium phosphate, 1 mg | 66 | $161 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 62 | $107 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 47 | $67 | None |
| Injection, furosemide, up to 20 mg | 12 | $12 | None |
| Infusion, normal saline solution, 250 cc | 14 | $7 | None |
2019: 49 services
| Injection, pembrolizumab, 1 mg | 13 | $566,729 | None |
| Injection, pemetrexed, not otherwise specified, 10 mg | 12 | $196,297 | None |
| Injection, rituximab, 10 mg | 21 | $187,221 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 21 | $130,570 | None |
| Injection, bevacizumab, 10 mg | 11 | $104,993 | None |
| Injection, denosumab, 1 mg | 30 | $90,340 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 23 | $86,566 | None |
| Injection, bortezomib, 0.1 mg | 12 | $80,427 | None |
| Injection, pegfilgrastim, 6 mg | 12 | $79,939 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 19 | $78,779 | None |
| Return visit (30+ min) | 396 | $73,646 | $93 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 17 | $68,220 | None |
| Administration of chemotherapy into vein, 1 hour or less | 148 | $67,319 | $150 |
| Long return visit (40+ min) | 139 | $42,044 | $131 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 115 | $19,931 | $75 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 20 | $15,815 | $84 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 25 | $14,902 | None |
| New patient visit (60+ min) | 66 | $12,324 | $187 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $9,001 | $94 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11 | $8,685 | $1 |
| Administration of additional new drug or substance into vein, 1 hour or less | 52 | $8,362 | $72 |
| Administration of chemotherapy into vein, each additional hour | 59 | $6,674 | $31 |
| Injection of additional new drug or substance into vein | 91 | $6,060 | $17 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,712 | $184 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 65 | $5,387 | $32 |
| Injection, fosaprepitant, 1 mg | 13 | $4,511 | None |
| Injection of drug or substance under skin or into muscle | 86 | $3,933 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 35 | $3,712 | $22 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 17 | $3,507 | $175 |
| Administration of additional new drug or substance into vein using push technique | 20 | $3,282 | $62 |
| New patient visit (45+ min) | 21 | $2,910 | $139 |
| Red blood cells, leukocytes reduced, each unit | 15 | $2,691 | $71 |
| Injection of drug or substance into vein | 49 | $2,399 | $36 |
| Irrigation of implanted venous access drug delivery device | 46 | $2,231 | $28 |
| Injection, zoledronic acid, 1 mg | 47 | $2,225 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 37 | $1,865 | $32 |
| Injection, carboplatin, 50 mg | 31 | $1,257 | None |
| Transfusion of blood or blood products | 18 | $1,103 | $38 |
| Injection, paclitaxel, 1 mg | 24 | $1,021 | None |
| Short return visit (20+ min) | 12 | $791 | $66 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 23 | $666 | $22 |
| Infusion into a vein for hydration, each additional hour | 13 | $526 | $14 |
| Collection of blood sample from implanted device | 14 | $506 | $27 |
| Injection, dexamethasone sodium phosphate, 1 mg | 71 | $193 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 61 | $171 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 55 | $84 | None |
| Infusion, normal saline solution, 250 cc | 50 | $27 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $24 | None |
| Injection, furosemide, up to 20 mg | 15 | $14 | None |
2018: 51 services
| Injection, pembrolizumab, 1 mg | 13 | $351,336 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 18 | $321,925 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 27 | $236,710 | None |
| Injection, rituximab, 100 mg | 13 | $207,939 | None |
| Injection, pegfilgrastim, 6 mg | 18 | $173,352 | None |
| Injection, denosumab, 1 mg | 29 | $157,973 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 13 | $150,891 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 12 | $84,561 | None |
| Administration of chemotherapy into vein, 1 hour or less | 120 | $75,011 | $149 |
| Return visit (30+ min) | 385 | $72,841 | $91 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 40 | $40,830 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 112 | $37,906 | $75 |
| Long return visit (40+ min) | 119 | $29,190 | $129 |
| New patient visit (60+ min) | 69 | $12,371 | $179 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $12,208 | $84 |
| Injection of additional new drug or substance into vein | 82 | $11,083 | $18 |
| Injection, fosaprepitant, 1 mg | 15 | $10,442 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 41 | $10,162 | $71 |
| Injection of drug or substance under skin or into muscle | 80 | $8,342 | $20 |
| Administration of chemotherapy into vein, each additional hour | 45 | $8,162 | $32 |
| Injection, tbo-filgrastim, 1 microgram | 12 | $7,033 | None |
| Injection of drug or substance into vein | 112 | $6,832 | $46 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 30 | $6,702 | $22 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $6,418 | $93 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11 | $5,954 | $1 |
| Injection, zoledronic acid, 1 mg | 102 | $5,655 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 51 | $4,130 | $32 |
| Bcg (intravesical) per instillation | 12 | $4,009 | None |
| Administration of additional new drug or substance into vein using push technique | 19 | $3,971 | $61 |
| New patient visit (45+ min) | 26 | $3,705 | $142 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 32 | $3,489 | $32 |
| Instillation of anti-cancer drug into bladder | 12 | $2,997 | $77 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 17 | $2,911 | $171 |
| Irrigation of implanted venous access drug delivery device | 29 | $2,832 | $27 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,547 | $182 |
| Injection, carboplatin, 50 mg | 27 | $2,269 | None |
| Drawing of blood for a medical problem | 11 | $2,059 | $90 |
| Injection, paclitaxel, 1 mg | 17 | $1,694 | None |
| Infusion into a vein for hydration, 31-60 minutes | 11 | $1,312 | $49 |
| Short return visit (20+ min) | 12 | $971 | $69 |
| Transfusion of blood or blood products | 15 | $932 | $37 |
| Collection of blood sample from implanted device | 14 | $926 | $26 |
| Infusion into a vein for hydration, each additional hour | 16 | $572 | $14 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 20 | $520 | $21 |
| Injection, dexamethasone sodium phosphate, 1 mg | 57 | $275 | None |
| Red blood cells, leukocytes reduced, each unit | 11 | $241 | $13 |
| Injection, ondansetron hydrochloride, per 1 mg | 46 | $144 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 44 | $102 | None |
| Infusion, normal saline solution, 250 cc | 22 | $67 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 11 | $54 | None |
| Injection, furosemide, up to 20 mg | 12 | $15 | None |
2017: 49 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 17 | $256,798 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 34 | $240,944 | None |
| Injection, rituximab, 100 mg | 19 | $182,520 | None |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 18 | $132,245 | None |
| Injection, pegfilgrastim, 6 mg | 17 | $115,477 | None |
| Injection, denosumab, 1 mg | 18 | $106,503 | None |
| Return visit (30+ min) | 357 | $67,241 | $91 |
| Administration of chemotherapy into vein, 1 hour or less | 120 | $60,625 | $143 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 13 | $47,013 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 11 | $35,342 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 101 | $31,162 | $71 |
| Long return visit (40+ min) | 106 | $30,001 | $128 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 35 | $29,964 | None |
| New patient visit (60+ min) | 71 | $12,886 | $181 |
| Injection of drug or substance into vein | 90 | $12,248 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $11,498 | $93 |
| Injection of additional new drug or substance into vein | 75 | $9,127 | $23 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $8,905 | $76 |
| Injection of drug or substance under skin or into muscle | 66 | $6,713 | $25 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $6,272 | $179 |
| Administration of additional new drug or substance into vein, 1 hour or less | 35 | $6,125 | $67 |
| Administration of chemotherapy into vein, each additional hour | 48 | $6,090 | $28 |
| Injection, fosaprepitant, 1 mg | 11 | $5,807 | None |
| Bcg (intravesical) per instillation | 13 | $5,255 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 32 | $5,022 | $19 |
| Instillation of anti-cancer drug into bladder | 13 | $4,413 | $83 |
| Injection, zoledronic acid, 1 mg | 78 | $3,865 | None |
| Biopsy of bone marrow | 22 | $3,711 | $169 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 44 | $3,633 | $33 |
| Red blood cells, leukocytes reduced, each unit | 12 | $3,474 | $91 |
| New patient visit (45+ min) | 22 | $2,770 | $126 |
| Drawing of blood for a medical problem | 14 | $2,289 | $100 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 22 | $1,680 | $31 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,571 | $98 |
| Administration of additional new drug or substance into vein using push technique | 13 | $1,544 | $64 |
| Transfusion of blood or blood products | 21 | $1,447 | $36 |
| Irrigation of implanted venous access drug delivery device | 21 | $1,381 | $24 |
| Infusion into a vein for hydration, each additional hour | 23 | $1,263 | $15 |
| Injection, carboplatin, 50 mg | 17 | $1,236 | None |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $1,138 | $60 |
| Influenza vaccine split virus, preservative free | 26 | $1,126 | $43 |
| Injection, paclitaxel, 1 mg | 14 | $1,039 | None |
| Administration of influenza virus vaccine | 26 | $838 | $32 |
| Injection, furosemide, up to 20 mg | 16 | $317 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 22 | $261 | $12 |
| Injection, dexamethasone sodium phosphate, 1 mg | 63 | $233 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 46 | $104 | None |
| Infusion, normal saline solution, 250 cc | 40 | $85 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 41 | $64 | None |
2016: 62 services
| Injection, infliximab, excludes biosimilar, 10 mg | 34 | $232,185 | None |
| Injection, bortezomib, 0.1 mg | 16 | $205,680 | None |
| Injection, bevacizumab, 10 mg | 13 | $194,319 | None |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 19 | $184,156 | None |
| Injection, rituximab, 100 mg | 15 | $174,847 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 16 | $162,309 | None |
| Injection, pegfilgrastim, 6 mg | 17 | $145,974 | None |
| Injection, denosumab, 1 mg | 22 | $77,795 | None |
| Return visit (30+ min) | 333 | $72,802 | $92 |
| Administration of chemotherapy into vein, 1 hour or less | 139 | $70,134 | $139 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 20 | $68,503 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 37 | $34,235 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 106 | $23,392 | $71 |
| Long return visit (40+ min) | 93 | $21,859 | $128 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $21,825 | $77 |
| New patient visit (60+ min) | 91 | $16,447 | $181 |
| Injection of additional new drug or substance into vein | 100 | $11,859 | $23 |
| Injection of drug or substance into vein | 81 | $11,351 | $58 |
| Injection, fosaprepitant, 1 mg | 17 | $11,121 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 49 | $9,788 | $64 |
| Injection, tbo-filgrastim, 1 microgram | 15 | $8,958 | None |
| Injection of drug or substance under skin or into muscle | 92 | $8,280 | $25 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $6,944 | $93 |
| Instillation of anti-cancer drug into bladder | 13 | $6,555 | $99 |
| Administration of chemotherapy into vein, each additional hour | 59 | $6,163 | $28 |
| Injection, zoledronic acid, 1 mg | 68 | $5,940 | None |
| Bcg (intravesical) per instillation | 11 | $5,500 | None |
| Administration of chemotherapy into vein using push technique | 12 | $5,491 | $114 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 41 | $5,357 | $18 |
| Administration of prolonged chemotherapy into vein | 14 | $5,324 | $144 |
| Red blood cells, leukocytes reduced, each unit | 17 | $4,776 | $77 |
| Administration of additional new drug or substance into vein using push technique | 22 | $4,676 | $63 |
| Biopsy of bone marrow | 25 | $4,349 | $167 |
| Infusion into a vein for hydration, 31-60 minutes | 15 | $4,297 | $59 |
| New patient visit (45+ min) | 29 | $3,859 | $133 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,855 | $175 |
| Injection, iron dextran, 50 mg | 13 | $3,560 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 54 | $3,500 | $32 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 33 | $3,076 | $30 |
| Infusion into a vein for hydration, each additional hour | 26 | $2,471 | $15 |
| Injection, carboplatin, 50 mg | 32 | $1,919 | None |
| Injection, paclitaxel, 1 mg | 24 | $1,651 | None |
| Drawing of blood for a medical problem | 12 | $1,603 | $100 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,556 | $97 |
| Irrigation of implanted venous access drug delivery device | 28 | $1,546 | $25 |
| Transfusion of blood or blood products | 17 | $1,096 | $37 |
| Short return visit (20+ min) | 20 | $1,038 | $52 |
| Injection, furosemide, up to 20 mg | 21 | $842 | None |
| Influenza vaccine split virus, preservative free | 18 | $655 | $36 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $581 | $20 |
| Injection, fluorouracil, 500 mg | 14 | $553 | None |
| Administration of influenza virus vaccine | 18 | $547 | $30 |
| Collection of blood sample from implanted device | 11 | $346 | $22 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $314 | $17 |
| Injection, dexamethasone sodium phosphate, 1 mg | 83 | $300 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 23 | $283 | $12 |
| Injection, ondansetron hydrochloride, per 1 mg | 70 | $166 | None |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 12 | $129 | None |
| Infusion, normal saline solution, 250 cc | 37 | $76 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 17 | $75 | None |
| 5% dextrose/normal saline (500 ml = 1 unit) | 13 | $73 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 54 | $66 | None |
2015: 44 services
| Injection, rituximab, 100 mg | 18 | $123,261 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 24 | $117,343 | None |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 19 | $111,022 | None |
| Injection, pegfilgrastim, 6 mg | 18 | $109,707 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 20 | $98,013 | None |
| Return visit (30+ min) | 326 | $67,499 | $96 |
| Administration of chemotherapy into vein, 1 hour or less | 126 | $45,997 | $145 |
| Injection, denosumab, 1 mg | 11 | $27,525 | None |
| Long return visit (40+ min) | 100 | $23,029 | $140 |
| Injection, tbo-filgrastim, 5 micrograms | 27 | $20,840 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 90 | $16,903 | $75 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 23 | $16,753 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $13,631 | $81 |
| New patient visit (60+ min) | 64 | $12,637 | $197 |
| Unclassified drugs | 14 | $12,024 | None |
| Injection, zoledronic acid, 1 mg | 69 | $11,291 | None |
| Injection of drug or substance under skin or into muscle | 93 | $9,452 | $26 |
| Injection of additional new drug or substance into vein | 95 | $9,421 | $24 |
| Injection of drug or substance into vein | 65 | $8,036 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $7,947 | $96 |
| Administration of additional new drug or substance into vein, 1 hour or less | 46 | $6,068 | $67 |
| Administration of chemotherapy into vein, each additional hour | 53 | $4,326 | $30 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 30 | $4,095 | $19 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,030 | $183 |
| Biopsy of bone marrow | 16 | $2,990 | $176 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 12 | $2,088 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 33 | $1,962 | $34 |
| New patient visit (45+ min) | 14 | $1,895 | $135 |
| Injection, paclitaxel, 1 mg | 28 | $1,814 | None |
| Short return visit (20+ min) | 24 | $1,781 | $69 |
| Injection, carboplatin, 50 mg | 32 | $1,761 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 31 | $1,760 | $32 |
| Administration of additional new drug or substance into vein using push technique | 12 | $1,532 | $67 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,530 | $102 |
| Irrigation of implanted venous access drug delivery device | 24 | $777 | $27 |
| Collection of blood sample from implanted device | 18 | $726 | $26 |
| Infusion into a vein for hydration, each additional hour | 14 | $562 | $16 |
| Injection, dexamethasone sodium phosphate, 1 mg | 76 | $208 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 16 | $199 | $12 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 13 | $150 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 63 | $89 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 16 | $87 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 53 | $49 | None |
| Infusion, normal saline solution, 250 cc | 12 | $21 | None |
2014: 40 services
| Injection, rituximab, 100 mg | 16 | $159,393 | None |
| Injection, pegfilgrastim, 6 mg | 24 | $134,545 | None |
| Return visit (30+ min) | 263 | $61,549 | $92 |
| Administration of chemotherapy into vein, 1 hour or less | 96 | $46,238 | $136 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 15 | $17,190 | None |
| Injection, docetaxel, 1 mg | 11 | $13,290 | None |
| Cyclophosphamide, 100 mg | 11 | $12,890 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $11,553 | $92 |
| Injection of additional new drug or substance into vein | 90 | $11,330 | $22 |
| Administration of additional new drug or substance into vein, 1 hour or less | 58 | $10,385 | $63 |
| New patient visit (60+ min) | 58 | $10,346 | $178 |
| Long return visit (40+ min) | 45 | $9,995 | $127 |
| Injection, fosaprepitant, 1 mg | 13 | $6,420 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $6,236 | $75 |
| Injection, zoledronic acid, 1 mg | 11 | $5,399 | None |
| Injection of drug or substance under skin or into muscle | 62 | $4,755 | $25 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,677 | $180 |
| Administration of chemotherapy into vein, each additional hour | 48 | $4,415 | $28 |
| Administration of additional new drug or substance into vein using push technique | 22 | $3,736 | $62 |
| Biopsy of bone marrow | 22 | $3,689 | $160 |
| Infusion into a vein for hydration, 31-60 minutes | 16 | $2,782 | $58 |
| Short return visit (20+ min) | 38 | $2,617 | $62 |
| New patient visit (45+ min) | 18 | $2,602 | $145 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 20 | $2,524 | $70 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 40 | $2,493 | $30 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 15 | $2,411 | None |
| Injection, carboplatin, 50 mg | 35 | $1,997 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 13 | $1,371 | $18 |
| Injection, paclitaxel, 30 mg | 20 | $1,023 | None |
| Infusion into a vein for hydration, each additional hour | 16 | $970 | $15 |
| Injection of drug or substance into vein | 12 | $857 | $57 |
| Irrigation of implanted venous access drug delivery device | 17 | $764 | $25 |
| Administration of influenza virus vaccine | 25 | $760 | $30 |
| Influenza vaccine split virus, preservative free | 19 | $621 | $33 |
| Injection, dexamethasone sodium phosphate, 1 mg | 83 | $329 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 20 | $247 | $12 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 11 | $166 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 67 | $138 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 44 | $56 | None |
| Infusion, normal saline solution, 250 cc | 14 | $35 | None |
2013: 47 services
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 18 | $109,452 | None |
| Injection, bevacizumab, 10 mg | 12 | $98,329 | None |
| Injection, rituximab, 100 mg | 11 | $85,747 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 20 | $70,537 | None |
| Return visit (30+ min) | 249 | $53,273 | $90 |
| Administration of chemotherapy into vein, 1 hour or less | 100 | $39,345 | $147 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 108 | $24,203 | $77 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 15 | $22,077 | None |
| Injection, zoledronic acid (zometa), 1 mg | 17 | $20,954 | None |
| Zoldedronic acid 1mg | 20 | $16,953 | $138 |
| Injection, zoledronic acid (reclast), 1 mg | 20 | $16,409 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 20 | $16,144 | None |
| Long return visit (40+ min) | 67 | $13,718 | $128 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 38 | $11,833 | $90 |
| New patient visit (60+ min) | 63 | $11,040 | $175 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $10,158 | $78 |
| Administration of additional new drug or substance into vein, 1 hour or less | 41 | $7,199 | $73 |
| Injection of additional new drug or substance into vein | 67 | $5,868 | $23 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 36 | $5,865 | $21 |
| Injection of drug or substance under skin or into muscle | 68 | $5,426 | $25 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,255 | $175 |
| Injection, palonosetron hcl, 25 mcg | 14 | $3,928 | None |
| Administration of chemotherapy into vein, each additional hour | 43 | $3,847 | $30 |
| New patient visit (45+ min) | 24 | $3,283 | $137 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 30 | $2,673 | $32 |
| Biopsy of bone marrow | 11 | $1,956 | $163 |
| Administration of additional new drug or substance into vein using push technique | 13 | $1,914 | $64 |
| Short return visit (20+ min) | 26 | $1,833 | $63 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 15 | $1,717 | None |
| Injection of drug or substance into vein | 11 | $1,639 | $59 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,422 | $95 |
| Injection, carboplatin, 50 mg | 25 | $1,383 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,316 | $63 |
| Injection, paclitaxel, 30 mg | 14 | $875 | None |
| Infusion into a vein for hydration, each additional hour | 14 | $763 | $15 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 14 | $663 | $18 |
| Irrigation of implanted venous access drug delivery device | 16 | $652 | $23 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $385 | $18 |
| Injection, ceftriaxone sodium, per 250 mg | 14 | $280 | None |
| Injection, furosemide, up to 20 mg | 12 | $195 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 46 | $171 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 61 | $154 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 14 | $42 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 24 | $32 | None |
| Injection, magnesium sulfate, per 500 mg | 12 | $25 | None |
| Infusion, normal saline solution , 1000 cc | 12 | $17 | None |
| 5% dextrose/normal saline (500 ml = 1 unit) | 12 | $16 | None |
Medicaid work
$47 in 2024
Medicaid paid $47 for 17 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Infusion, normal saline solution, 250 cc | 17 | $47 |
| 2024 | 17 | 1 | 15 | $47 |
| 2023 | 13 | 1 | 12 | $446 |
| 2022 | 12 | 1 | 12 | $277 |
| 2021 | 26 | 1 | 13 | $693 |
| 2019 | 14 | 1 | 14 | $618 |
| 2018 | 12 | 1 | 12 | $944 |
See the largest Medicaid services in earlier years
2023
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 13 | $446 |
2022
| Long return visit (40+ min) | 12 | $277 |
2021
| Long return visit (40+ min) | 26 | $693 |
2019
| Return visit (30+ min) | 14 | $618 |
2018
| Return visit (30+ min) | 12 | $944 |
Drugs they prescribed that Part D paid
$5,287,485
Pharmacies billed $5,287,485 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
849 generic and fewer than 11 brand-name prescriptions · $5,287,485 in drug cost · 68 antibiotic prescriptions to 24 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Brukinsa | 38 | $572,856 | $15,075 |
| Pomalyst | 26 | $562,466 | $21,633 |
| Revlimid | 28 | $514,199 | $18,364 |
| Tagrisso | 31 | $503,168 | $16,231 |
| Lenalidomide | 35 | $451,339 | $12,895 |
See all 28 drugs
| Brukinsa | 38 | $572,856 | $15,075 |
| Pomalyst | 26 | $562,466 | $21,633 |
| Revlimid | 28 | $514,199 | $18,364 |
| Tagrisso | 31 | $503,168 | $16,231 |
| Lenalidomide | 35 | $451,339 | $12,895 |
| Tasigna | 18 | $381,436 | $21,191 |
| Erleada | 24 | $340,440 | $14,185 |
| Eliquis | 164 | $223,716 | $1,364 |
| Besremi | 12 | $219,645 | $18,304 |
| Sprycel | 12 | $137,328 | $11,444 |
| Promacta | 11 | $92,117 | $8,374 |
| Abiraterone Acetate | 44 | $59,470 | $1,352 |
| Xarelto | 29 | $41,124 | $1,418 |
| Atovaquone | 11 | $4,504 | $409 |
| Anastrozole | 116 | $2,529 | $22 |
| Acyclovir | 125 | $2,450 | $20 |
| Hydroxyurea | 66 | $1,880 | $28 |
| Exemestane | 15 | $1,257 | $84 |
| Imatinib Mesylate | 14 | $1,178 | $84 |
| Dexamethasone | 27 | $507 | $19 |
| Sulfamethoxazole-Trimethoprim | 49 | $507 | $10 |
| Letrozole | 22 | $450 | $20 |
| Prednisone | 67 | $428 | $6 |
| Prochlorperazine Maleate | 48 | $405 | $8 |
| Potassium Chloride | 18 | $203 | $11 |
| Ondansetron | 27 | $170 | $6 |
| Methylprednisolone | 11 | $73 | $7 |
| Allopurinol | 11 | $69 | $6 |
Year by year
| 2024 | 1,320 | 235 | None | None | $5,287,485 |
| 2023 | 1,310 | 213 | None | None | $4,745,219 |
| 2022 | 1,298 | 224 | None | None | $4,743,494 |
| 2021 | 1,273 | 212 | None | None | $4,257,447 |
| 2020 | 1,215 | 208 | 2% (20) | 36% | $3,320,765 |
| 2019 | 1,363 | 202 | 4% (57) | 34% | $2,787,408 |
| 2018 | 1,372 | 200 | 7% (99) | 27% | $2,577,639 |
| 2017 | 1,432 | 192 | 8% (116) | 25% | $2,017,475 |
| 2016 | 1,260 | 175 | 8% (100) | None | $1,068,912 |
| 2015 | 952 | 146 | 8% (72) | 18% | $674,007 |
| 2014 | 927 | 124 | 11% (103) | 21% | $901,311 |
| 2013 | 866 | 115 | 11% (92) | None | $841,395 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 29 drugs
| Revlimid | 44 | $730,981 | $16,613 |
| Imbruvica | 41 | $609,220 | $14,859 |
| Pomalyst | 27 | $582,934 | $21,590 |
| Lenvima | 14 | $319,222 | $22,802 |
| Calquence | 16 | $260,621 | $16,289 |
| Brukinsa | 15 | $225,084 | $15,006 |
| Tagrisso | 12 | $225,081 | $18,757 |
| Lenalidomide | 11 | $219,426 | $19,948 |
| Besremi | 14 | $218,016 | $15,573 |
| Eliquis | 175 | $205,711 | $1,175 |
| Erleada | 13 | $193,441 | $14,880 |
| Jakafi | 11 | $178,842 | $16,258 |
| Sprycel | 16 | $135,836 | $8,490 |
| Promacta | 12 | $87,315 | $7,276 |
| Abiraterone Acetate | 53 | $81,232 | $1,533 |
| Xarelto | 21 | $30,952 | $1,474 |
| Anastrozole | 121 | $3,745 | $31 |
| Acyclovir | 112 | $3,546 | $32 |
| Exemestane | 27 | $2,679 | $99 |
| Hydroxyurea | 69 | $2,030 | $29 |
| Imatinib Mesylate | 13 | $2,004 | $154 |
| Prednisone | 86 | $710 | $8 |
| Prochlorperazine Maleate | 39 | $623 | $16 |
| Potassium Chloride | 38 | $465 | $12 |
| Letrozole | 26 | $344 | $13 |
| Sulfamethoxazole-Trimethoprim | 45 | $333 | $7 |
| Dexamethasone | 24 | $329 | $14 |
| Ondansetron | 21 | $276 | $13 |
| Gabapentin | 12 | $123 | $10 |
2022: 28 drugs
| Pomalyst | 53 | $1,091,513 | $20,595 |
| Imbruvica | 62 | $906,739 | $14,625 |
| Revlimid | 46 | $854,742 | $18,581 |
| Jakafi | 17 | $278,226 | $16,366 |
| Sprycel | 22 | $200,192 | $9,100 |
| Eliquis | 152 | $188,900 | $1,243 |
| Erleada | 14 | $188,462 | $13,462 |
| Calquence | 11 | $167,244 | $15,204 |
| Besremi | 11 | $159,175 | $14,470 |
| Kisqali | 12 | $140,872 | $11,739 |
| Abiraterone Acetate | 35 | $60,343 | $1,724 |
| Xarelto | 25 | $31,916 | $1,277 |
| Acyclovir | 108 | $4,777 | $44 |
| Anastrozole | 141 | $4,473 | $32 |
| Hydroxyurea | 68 | $2,297 | $34 |
| Exemestane | 16 | $1,807 | $113 |
| Imatinib Mesylate | 12 | $1,643 | $137 |
| Dexamethasone | 42 | $1,106 | $26 |
| Prochlorperazine Maleate | 82 | $1,016 | $12 |
| Potassium Chloride | 23 | $640 | $28 |
| Prednisone | 54 | $576 | $11 |
| Letrozole | 14 | $458 | $33 |
| Gabapentin | 14 | $442 | $32 |
| Ondansetron | 29 | $411 | $14 |
| Tamoxifen Citrate | 12 | $268 | $22 |
| Sulfamethoxazole-Trimethoprim | 31 | $218 | $7 |
| Levothyroxine | 13 | $164 | $13 |
| Allopurinol | 16 | $158 | $10 |
2021: 27 drugs
| Imbruvica | 78 | $1,092,520 | $14,007 |
| Revlimid | 55 | $956,264 | $17,387 |
| Pomalyst | 33 | $643,616 | $19,504 |
| Jakafi | 22 | $337,567 | $15,344 |
| Erleada | 21 | $274,310 | $13,062 |
| Sprycel | 22 | $184,390 | $8,381 |
| Eliquis | 147 | $152,614 | $1,038 |
| Imatinib Mesylate | 24 | $82,251 | $3,427 |
| Xarelto | 20 | $24,244 | $1,212 |
| Abiraterone Acetate | 16 | $14,554 | $910 |
| Anastrozole | 174 | $6,381 | $37 |
| Acyclovir | 111 | $4,436 | $40 |
| Hydroxyurea | 74 | $3,019 | $41 |
| Exemestane | 20 | $2,482 | $124 |
| Dexamethasone | 48 | $1,538 | $32 |
| Prochlorperazine Maleate | 55 | $737 | $13 |
| Potassium Chloride | 14 | $457 | $33 |
| Letrozole | 17 | $448 | $26 |
| Prednisone | 47 | $391 | $8 |
| Gabapentin | 13 | $362 | $28 |
| Levothyroxine | 16 | $357 | $22 |
| Pantoprazole | 11 | $337 | $31 |
| Sulfamethoxazole-Trimethoprim | 34 | $305 | $9 |
| Ondansetron | 23 | $297 | $13 |
| Tamoxifen Citrate | 14 | $198 | $14 |
| Mirtazapine | 11 | $118 | $11 |
| Allopurinol | 11 | $50 | $5 |
2020: 26 drugs
| Imbruvica | 89 | $1,242,552 | $13,961 |
| Revlimid | 35 | $556,306 | $15,894 |
| Pomalyst | 25 | $483,777 | $19,351 |
| Sprycel | 22 | $182,899 | $8,314 |
| Jakafi | 12 | $175,698 | $14,642 |
| Eliquis | 119 | $92,145 | $774 |
| Imatinib Mesylate | 18 | $63,949 | $3,553 |
| Abiraterone Acetate | 25 | $42,872 | $1,715 |
| Xarelto | 27 | $26,207 | $971 |
| Exemestane | 33 | $8,870 | $269 |
| Anastrozole | 166 | $6,045 | $36 |
| Acyclovir | 121 | $4,215 | $35 |
| Hydroxyurea | 61 | $2,634 | $43 |
| Dexamethasone | 29 | $932 | $32 |
| Prochlorperazine Maleate | 55 | $677 | $12 |
| Pantoprazole | 17 | $510 | $30 |
| Ondansetron | 28 | $510 | $18 |
| Letrozole | 16 | $434 | $27 |
| Tamoxifen Citrate | 14 | $420 | $30 |
| Prednisone | 45 | $396 | $9 |
| Levothyroxine | 14 | $269 | $19 |
| Potassium Chloride | 18 | $259 | $14 |
| Gabapentin | 12 | $233 | $19 |
| Allopurinol | 12 | $190 | $16 |
| Hydrocodone-Acetaminophen | 11 | $119 | $11 |
| Sulfamethoxazole-Trimethoprim | 27 | $113 | $4 |
2019: 32 drugs
| Imbruvica | 83 | $1,049,150 | $12,640 |
| Revlimid | 25 | $398,940 | $15,958 |
| Tagrisso | 19 | $309,343 | $16,281 |
| Jakafi | 12 | $166,588 | $13,882 |
| Sprycel | 17 | $135,634 | $7,978 |
| Tarceva | 12 | $107,108 | $8,926 |
| Eliquis | 145 | $85,408 | $589 |
| Abiraterone Acetate | 24 | $81,981 | $3,416 |
| Xarelto | 39 | $28,986 | $743 |
| Vemlidy | 20 | $22,965 | $1,148 |
| Imatinib Mesylate | 11 | $21,623 | $1,966 |
| Creon | 11 | $18,050 | $1,641 |
| Exemestane | 36 | $13,966 | $388 |
| Enoxaparin | 11 | $6,940 | $631 |
| Anastrozole | 170 | $4,445 | $26 |
| Acyclovir | 135 | $3,438 | $25 |
| Hydroxyurea | 69 | $3,367 | $49 |
| Morphine Sulfate Er | 21 | $976 | $46 |
| Dexamethasone | 35 | $908 | $26 |
| Fentanyl | 13 | $890 | $68 |
| Tamoxifen Citrate | 21 | $717 | $34 |
| Prochlorperazine Maleate | 43 | $585 | $14 |
| Prednisone | 53 | $519 | $10 |
| Gabapentin | 15 | $495 | $33 |
| Levothyroxine | 17 | $450 | $26 |
| Ondansetron | 29 | $388 | $13 |
| Pantoprazole | 16 | $373 | $23 |
| Letrozole | 18 | $360 | $20 |
| Potassium Chloride | 11 | $345 | $31 |
| Allopurinol | 13 | $134 | $10 |
| Sulfamethoxazole-Trimethoprim | 12 | $85 | $7 |
| Citalopram Hbr | 12 | $60 | $5 |
2018: 29 drugs
| Imbruvica | 68 | $800,862 | $11,777 |
| Zytiga | 29 | $292,481 | $10,086 |
| Revlimid | 21 | $285,868 | $13,613 |
| Pomalyst | 13 | $273,772 | $21,059 |
| Jakafi | 15 | $194,403 | $12,960 |
| Tarceva | 12 | $107,108 | $8,926 |
| Sprycel | 13 | $100,610 | $7,739 |
| Eliquis | 111 | $69,347 | $625 |
| Exemestane | 34 | $18,806 | $553 |
| Creon | 12 | $18,678 | $1,557 |
| Hydroxyurea | 60 | $3,539 | $59 |
| Anastrozole | 154 | $3,020 | $20 |
| Acyclovir | 140 | $2,725 | $19 |
| Fentanyl | 24 | $1,603 | $67 |
| Tamoxifen Citrate | 25 | $863 | $35 |
| Morphine Sulfate Er | 19 | $845 | $44 |
| Bicalutamide | 34 | $790 | $23 |
| Dexamethasone | 28 | $539 | $19 |
| Prednisone | 44 | $499 | $11 |
| Hydrocodone-Acetaminophen | 23 | $487 | $21 |
| Gabapentin | 24 | $430 | $18 |
| Pantoprazole | 14 | $337 | $24 |
| Levothyroxine | 11 | $333 | $30 |
| Ondansetron | 33 | $324 | $10 |
| Prochlorperazine Maleate | 39 | $322 | $8 |
| Letrozole | 20 | $296 | $15 |
| Lorazepam | 29 | $172 | $6 |
| Tramadol | 20 | $133 | $7 |
| Trazodone | 13 | $85 | $7 |
2017: 35 drugs
| Revlimid | 41 | $519,397 | $12,668 |
| Imbruvica | 40 | $454,095 | $11,352 |
| Zytiga | 22 | $208,580 | $9,481 |
| Tarceva | 22 | $159,399 | $7,245 |
| Promacta | 19 | $126,207 | $6,642 |
| Sprycel | 11 | $96,639 | $8,785 |
| Eliquis | 79 | $38,873 | $492 |
| Exemestane | 39 | $19,623 | $503 |
| Creon | 12 | $17,131 | $1,428 |
| Xarelto | 18 | $9,351 | $520 |
| Hydroxyurea | 62 | $3,697 | $60 |
| Anastrozole | 144 | $3,540 | $25 |
| Acyclovir | 161 | $2,737 | $17 |
| Fentanyl | 28 | $2,206 | $79 |
| Morphine Sulfate Er | 30 | $1,600 | $53 |
| Gabapentin | 42 | $1,214 | $29 |
| Potassium Chloride | 13 | $831 | $64 |
| Bicalutamide | 31 | $727 | $23 |
| Prednisone | 40 | $528 | $13 |
| Tamoxifen Citrate | 16 | $478 | $30 |
| Duloxetine | 19 | $454 | $24 |
| Prochlorperazine Maleate | 52 | $422 | $8 |
| Levothyroxine | 15 | $414 | $28 |
| Hydrocodone-Acetaminophen | 32 | $372 | $12 |
| Dexamethasone | 25 | $315 | $13 |
| Ondansetron | 34 | $308 | $9 |
| Omeprazole | 13 | $285 | $22 |
| Allopurinol | 17 | $225 | $13 |
| Pantoprazole | 15 | $153 | $10 |
| Lorazepam | 38 | $142 | $4 |
| Tramadol | 17 | $121 | $7 |
| Amitriptyline | 11 | $101 | $9 |
| Mirtazapine | 14 | $88 | $6 |
| Sulfamethoxazole-Trimethoprim | 15 | $88 | $6 |
| Trazodone | 11 | $76 | $7 |
2016: 31 drugs
| Revlimid | 36 | $405,646 | $11,268 |
| Zytiga | 20 | $171,003 | $8,550 |
| Creon | 13 | $16,258 | $1,251 |
| Xarelto | 31 | $14,452 | $466 |
| Eliquis | 23 | $13,152 | $572 |
| Exemestane | 36 | $11,808 | $328 |
| Lamivudine Hbv | 16 | $7,307 | $457 |
| Enoxaparin | 14 | $5,701 | $407 |
| Duloxetine | 20 | $3,710 | $186 |
| Anastrozole | 126 | $2,915 | $23 |
| Hydroxyurea | 58 | $2,764 | $48 |
| Acyclovir | 128 | $2,124 | $17 |
| Gabapentin | 49 | $1,061 | $22 |
| Fentanyl | 11 | $756 | $69 |
| Hydrocodone-Acetaminophen | 44 | $742 | $17 |
| Dexamethasone | 38 | $688 | $18 |
| Morphine Sulfate Er | 12 | $560 | $47 |
| Ondansetron | 38 | $490 | $13 |
| Omeprazole | 27 | $427 | $16 |
| Prochlorperazine Maleate | 58 | $395 | $7 |
| Tamoxifen Citrate | 17 | $377 | $22 |
| Pantoprazole | 18 | $333 | $18 |
| Prednisone | 31 | $312 | $10 |
| Levothyroxine | 17 | $308 | $18 |
| Bicalutamide | 14 | $280 | $20 |
| Lorazepam | 43 | $215 | $5 |
| Sulfamethoxazole-Trimethoprim | 18 | $187 | $10 |
| Mirtazapine | 14 | $173 | $12 |
| Tramadol | 12 | $126 | $11 |
| Zolpidem | 13 | $67 | $5 |
| Amitriptyline | 12 | $59 | $5 |
2015: 27 drugs
| Gleevec | 14 | $164,201 | $11,729 |
| Xarelto | 28 | $12,079 | $431 |
| Enoxaparin | 13 | $10,821 | $832 |
| Exemestane | 27 | $9,610 | $356 |
| Cyclophosphamide | 11 | $4,249 | $386 |
| Eliquis | 11 | $3,695 | $336 |
| Hydroxyurea | 37 | $2,126 | $57 |
| Anastrozole | 110 | $2,082 | $19 |
| Avodart | 11 | $2,063 | $188 |
| Duloxetine | 16 | $1,536 | $96 |
| Acyclovir | 84 | $1,266 | $15 |
| Hydrocodone-Acetaminophen | 26 | $874 | $34 |
| Gabapentin | 39 | $734 | $19 |
| Morphine Sulfate Er | 13 | $522 | $40 |
| Levothyroxine | 18 | $459 | $25 |
| Ondansetron | 32 | $437 | $14 |
| Omeprazole | 27 | $355 | $13 |
| Dexamethasone | 22 | $285 | $13 |
| Pantoprazole | 15 | $234 | $16 |
| Tamoxifen Citrate | 12 | $224 | $19 |
| Prochlorperazine Maleate | 32 | $191 | $6 |
| Zolpidem | 13 | $189 | $15 |
| Sulfamethoxazole-Trimethoprim | 12 | $182 | $15 |
| Lorazepam | 32 | $176 | $5 |
| Tramadol | 12 | $119 | $10 |
| Amitriptyline | 12 | $81 | $7 |
| Furosemide | 16 | $53 | $3 |
2014: 25 drugs
| Revlimid | 34 | $256,810 | $7,553 |
| Tarceva | 21 | $143,660 | $6,841 |
| Zytiga | 21 | $142,665 | $6,794 |
| Jakafi | 12 | $110,120 | $9,177 |
| Xarelto | 25 | $9,728 | $389 |
| Exemestane | 16 | $4,594 | $287 |
| Anastrozole | 137 | $4,542 | $33 |
| Hydroxyurea | 35 | $1,608 | $46 |
| Acyclovir | 70 | $1,575 | $23 |
| Fentanyl | 11 | $933 | $85 |
| Hydrocodone-Acetaminophen | 25 | $667 | $27 |
| Morphine Sulfate Er | 17 | $530 | $31 |
| Gabapentin | 34 | $528 | $16 |
| Omeprazole | 33 | $526 | $16 |
| Pantoprazole | 17 | $391 | $23 |
| Letrozole | 14 | $372 | $27 |
| Tamoxifen Citrate | 17 | $349 | $21 |
| Prochlorperazine Maleate | 35 | $315 | $9 |
| Prednisone | 27 | $304 | $11 |
| Ondansetron | 13 | $227 | $17 |
| Dexamethasone | 15 | $219 | $15 |
| Tramadol | 25 | $204 | $8 |
| Mirtazapine | 16 | $180 | $11 |
| Lorazepam | 19 | $114 | $6 |
| Furosemide | 16 | $55 | $3 |
2013: 23 drugs
| Revlimid | 32 | $242,341 | $7,573 |
| Tarceva | 16 | $105,946 | $6,622 |
| Zytiga | 15 | $98,595 | $6,573 |
| Exemestane | 21 | $8,152 | $388 |
| Xarelto | 14 | $3,740 | $267 |
| Anastrozole | 99 | $3,694 | $37 |
| Hydroxyurea | 44 | $1,750 | $40 |
| Acyclovir | 44 | $920 | $21 |
| Letrozole | 15 | $910 | $61 |
| Pantoprazole | 43 | $838 | $19 |
| Gabapentin | 31 | $514 | $17 |
| Hydrocodone-Acetaminophen | 37 | $483 | $13 |
| Tamoxifen Citrate | 20 | $421 | $21 |
| Morphine Sulfate Er | 12 | $312 | $26 |
| Prochlorperazine Maleate | 25 | $232 | $9 |
| Omeprazole | 21 | $228 | $11 |
| Prednisone | 30 | $214 | $7 |
| Mirtazapine | 21 | $170 | $8 |
| Zolpidem | 15 | $152 | $10 |
| Lorazepam | 25 | $146 | $6 |
| Tramadol | 16 | $137 | $9 |
| Dexamethasone | 11 | $98 | $9 |
| Furosemide | 19 | $89 | $5 |
Money from drug and device companies
$191 in 2025
| 2025 | 4 | 4 | None | $191 |
| 2024 | 1 | 1 | None | $17 |
| 2023 | 2 | 2 | None | $38 |
| 2022 | 2 | 2 | None | $44 |
| 2021 | 2 | 2 | None | $25 |
| 2020 | 1 | 1 | $175 | $175 |
| 2019 | 3 | 4 | None | $49 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Lynparza | $125 | 1 payment
|
| Abbvie | Imbruvica | $26 | 1 payment
|
| Array Biopharma | Lorbrena | $25 | 1 payment
|
| Pfizer | Ibrance | $16 | 1 payment
|
See all 4 published payments
| Abbvie | Meals · 2025-07-22 | Imbruvica | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-17 | Lynparza | $125 |
| Array Biopharma | Meals · 2025-07-08 | Lorbrena | $25 |
| Pfizer | Education · 2025-04-28 | Ibrance | $16 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $17
| Daiichi Sankyo | Enhertu | $17 | 1 payment
|
2023: $38
| Pfizer | Ibrance | $25 | 1 payment
|
| Janssen Pharmaceuticals | None | $13 | 1 payment
|
2022: $44
| Pfizer | Ibrance | $32 | 1 payment
|
| PharmaEssentia USA | Besremi | $12 | 1 payment
|
2021: $25
| Pfizer | Inlyta | $13 | 1 payment
|
| Gilead Sciences | None | $12 | 1 payment
|
2020: $175
| Athenex Pharmaceutical Division | None | $175 | 1 payment
|
2019: $49
| American Orthodontics | Empower-Metal | $25 | 1 payment
|
| Seattle Genetics | Adcetris | $12 | 1 payment
|
| Pfizer | Ibrance | $12 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme Corporation · A Randomized, Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 Cm Residual Invasive Cancer Or Positive Lymph Nodes Pn1mic After Neoadjuvant Chemotherapy · 2020 | Their institution | $96 |
Professional record
- NPI
- 1194941104
- Licence
- CA A82274California A82274: Current · expires 2027-01-31
- Trained
- University of California, Geffen School of Medicine, 2001
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 2350 W El Camino Real, 2nd Floor, Mountain View, CA, 94040
- NPI first listed
- 2007-04-18
- NPI last updated
- 2011-12-02
This is when the NPI record was last certified, not a medical board exam.